Amyloidosis Treatment Market Size, Share & Trends Analysis Report
商品番号 : SMB-88129
| 出版社 | Grand View Research |
| 出版年月 | 2025年8月 |
| ページ数 | 130 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 5,950 |
| 種別 | 英文調査報告書 |
アミロイドーシス治療市場 – 治療（化学療法、免疫抑制剤、移植、支持療法）、最終用途（病院・診療所）、地域、セグメント別予測による市場規模、成長と動向分析レポート 2025-2033年
世界のアミロイドーシス治療市場規模は、2024年には58億米ドルと推定され、2033年には111億3000万米ドルに達すると予測されており、2025年から2033年にかけて年平均成長率7.5%で成長する見込みです。この業界は、この疾患に対する認知度の高まり、診断方法の進歩、そしてより早い段階で正確な診断によって特定される患者数の増加により、成長を遂げています。
高度な画像診断、質量分析、遺伝子検査といった技術革新により、医療従事者はアミロイドーシスのサブタイプをより正確に判別できるようになり、より正確で効果的な治療アプローチが実現しています。専門ケアセンターの設立と訓練を受けた医療専門家の確保により、包括的なケアへのアクセスがさらに向上しています。さらに、加齢性トランスサイレチンアミロイドーシスの発症率、特に高齢者層での増加は、長期的な治療ソリューションへの需要を高めています。これらの要因により、製薬会社は研究パイプラインの拡充を進めており、アミロイドーシスは適切な治療によって効果的に管理できる疾患であるという認識が、世界中の患者ケアの実践を変革しています。
Amyloidosis Treatment Market Summary
The global amyloidosis treatment market size was estimated at USD 5.80 billion in 2024 and is projected to reach USD 11.13 billion by 2033, growing at a CAGR of 7.5% from 2025 to 2033. The industry is experiencing growth due to rising awareness of the disease, advancements in diagnostic methods, and an increasing number of patients being identified at earlier stages with accurate diagnoses.
Innovations such as advanced imaging, mass spectrometry, and genetic testing are allowing healthcare providers to better distinguish between amyloidosis subtypes, supporting more precise and effective treatment approaches. The establishment of specialized care centers and the availability of trained medical experts are further enhancing access to comprehensive care. Additionally, the growing incidence of age-related transthyretin amyloidosis, particularly among older populations, is driving demand for long-term therapeutic solutions. These factors are prompting pharmaceutical companies to expand their research pipelines, while the recognition of amyloidosis as a condition that can be effectively managed with timely treatment is transforming global patient care practices.
One of the key drivers fueling the amyloidosis treatment market is the regulatory advancement of gene-silencing therapies for transthyretin amyloidosis. For instance, in March 2025, the U.S. FDA approved Amvuttra (vutrisiran) as the first gene-silencing therapy for transthyretin amyloid cardiomyopathy (ATTR-CM). The approval was backed by Phase III HELIOS-B trial results showing a 28% reduction in all-cause mortality and cardiovascular events. Patients also experienced notable improvements in functional capacity and quality of life. This advancement offers a new treatment pathway directly reducing TTR protein production with only four annual injections. The approval is expected to boost early diagnosis, expand RNA-based therapy adoption, and intensify competition in the ATTR-CM market.
The regulatory approval of highly effective small-molecule stabilizers targeting transthyretin amyloidosis is a major development boosting the amyloidosis treatment market. For instance , in December 2024, the U.S. FDA approved Attruby (acoramidis), a near-complete transthyretin (TTR) stabilizer developed by BridgeBio Pharma, for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) (BridgeBio). Acoramidis demonstrated over 90% stabilization of TTR and significantly reduced cardiovascular death and hospitalizations in the pivotal ATTRibute-CM trial. The approval introduces a convenient oral alternative that expands treatment options beyond RNAi-based therapies and meets the needs of a broader patient base. It is expected to intensify market competition and accelerate innovation in ATTR-CM therapeutics. With improved efficacy, tolerability, and ease of administration, acoramidis is positioned to reshape treatment paradigms for newly diagnosed and long-term ATTR-CM patients.
The projected surge in cancer cases, with the United States expected to see a 47.5% increase and Canada a 60.7% increase by 2050, the rising prevalence of chronic and complex diseases. This trend emphasizes the growing strain on healthcare systems, which in turn accelerates demand for advanced diagnostics and treatment solutions. Given that cancer and amyloidosis share overlapping clinical challenges such as organ dysfunction, protein misfolding, and systemic inflammation, the increase in cancer incidence indirectly raises awareness and identification of related conditions like amyloidosis. This linkage is likely to enhance patient screening, expand healthcare investments, and strengthen treatment infrastructure.
Consequently, the industry is expected to benefit from these dynamics as rising cancer prevalence fuels both clinical awareness and therapeutic innovation. With heightened demand for precision therapies, there will be an increased focus on monoclonal antibodies, targeted treatments, and supportive care solutions that address disease progression more effectively. Moreover, pharmaceutical companies and healthcare providers are likely to increase research funding and collaborations, leveraging advancements in oncology to accelerate drug development for amyloidosis. This synergy will position the amyloidosis market for significant growth in the coming decades.
Amyloidosis Treatment Market Report Scope
| Report Attribute | Details |
| Market size value in 2025 | USD 6.23 billion |
| Revenue forecast in 2033 | USD 11.13 billion |
| Growth rate | CAGR of 7.5% from 2025 to 2033 |
| Base year for estimation | 2024 |
| Historical data | 2021 – 2023 |
| Forecast period | 2025 – 2033 |
| Quantitative units | Revenue in USD million/billion and CAGR from 2025 to 2033 |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, trends |
| Segments covered | Treatment, end use, region |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
| Key company profiled | Pfizer Inc.; Johnson & Johnson Services, Inc.; GSK plc; Takeda Pharmaceutical Company Limited; Amgen Inc.; Bristol-Myers Squibb Company; Novartis AG; F. Hoffmann-La Roche Ltd; Merck KGaA; Sanofi; Alnylam Pharmaceuticals, Inc. |
| Customization scope | Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Global Amyloidosis Treatment Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global amyloidosis treatment market report based on treatment, end-use, and region:
- Treatment Outlook (Revenue, USD Million, 2021 – 2033)
- Chemotherapy
- Immunosuppressive Drugs
- Transplantation
- Supportive Care
- Surgery
- Others
- End Use Outlook (Revenue, USD Million, 2021 – 2033)
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Home Care Settings
- Others
- Regional Outlook (Revenue, USD Million, 2021 – 2033)
- North America
o U.S.
o Canada
o Mexico
- Europe
o UK
o Germany
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
- Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
o Thailand
- Latin America
o Brazil
o Argentina
- Middle East & Africa
o South Africa
o Saudi Arabia
o UAE
o Kuwait
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment
1.2.2. End-use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Amyloidosis Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis – Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Amyloidosis Treatment Market: Treatment Business Analysis
4.1. Treatment Market Share, 2024 & 2033
4.2. Treatment Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
4.4. Chemotherapy
4.4.1. Chemotherapy Market, 2021 – 2033 (USD Million)
4.5. Immunosuppressive Drugs
4.5.1. Immunosuppressive Drugs Market, 2021 – 2033 (USD Million)
4.6. Transplantation
4.6.1. Transplantation Market, 2021 – 2033 (USD Million)
4.7. Supportive Care
4.7.1. Supportive Care Market, 2021 – 2033 (USD Million)
4.8. Surgery
4.8.1. Surgery Market, 2021 – 2033 (USD Million)
4.9. Others
4.9.1. Others Market, 2021 – 2033 (USD Million)
Chapter 5. Amyloidosis Treatment Market: End Use Business Analysis
5.1. End Use Market Share, 2024 & 2033
5.2. End Use Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
5.4. Hospitals & Clinics
5.4.1. Hospitals & Clinics Market, 2021 – 2033 (USD Million)
5.5. Ambulatory Surgical Centers
5.5.1. Ambulatory Surgical Centers Market, 2021 – 2033 (USD Million)
5.6. Home Care Settings
5.6.1. Home Care Settings Market, 2021 – 2033 (USD Million)
5.7. Others
5.7.1. Others Market, 2021 – 2033 (USD Million)
Chapter 6. Amyloidosis Treatment Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2033
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
6.4. North America
6.4.1. North America Amyloidosis Treatment Market Estimates and Forecasts, By Country, 2021 – 2033 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. U.S. Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. U.S. Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. Mexico Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5. Europe
6.5.1. Europe Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. Uk Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. Germany Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Framework
6.5.4.5. France Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Regulatory Framework
6.5.5.4. Reimbursement Framework
6.5.5.5. Italy Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Target Disease Prevalence
6.5.6.3. Regulatory Framework
6.5.6.4. Reimbursement Framework
6.5.6.5. Spain Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Target Disease Prevalence
6.5.7.3. Regulatory Framework
6.5.7.4. Reimbursement Framework
6.5.7.5. Denmark Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamics
6.5.8.2. Target Disease Prevalence
6.5.8.3. Regulatory Framework
6.5.8.4. Reimbursement Framework
6.5.8.5. Sweden Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Target Disease Prevalence
6.5.9.3. Regulatory Framework
6.5.9.4. Reimbursement Framework
6.5.9.5. Norway Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. Japan Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. China Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. India Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Australia Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Regulatory Framework
6.6.6.4. Reimbursement Framework
6.6.6.5. South Korea Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Target Disease Prevalence
6.6.7.3. Regulatory Framework
6.6.7.4. Reimbursement Framework
6.6.7.5. Thailand Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.7. Latin America
6.7.1. Latin America Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Target Disease Prevalence
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Framework
6.7.2.5. Japan Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Target Disease Prevalence
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Framework
6.7.3.5. China Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Target Disease Prevalence
6.8.2.3. Regulatory Framework
6.8.2.4. Reimbursement Framework
6.8.2.5. South Africa Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Target Disease Prevalence
6.8.3.3. Regulatory Framework
6.8.3.4. Reimbursement Framework
6.8.3.5. Saudi Arabia Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Target Disease Prevalence
6.8.4.3. Regulatory Framework
6.8.4.4. Reimbursement Framework
6.8.4.5. UAE Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Target Disease Prevalence
6.8.5.3. Regulatory Framework
6.8.5.4. Reimbursement Framework
6.8.5.5. Kuwait Amyloidosis Treatment Market Estimates and Forecasts, 2021 – 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Pfizer Inc.
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Treatment Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Johnson & Johnson Services, Inc.
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Treatment Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. GSK plc
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Treatment Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Takeda Pharmaceutical Company Limited
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Treatment Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Amgen Inc.
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Treatment Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Bristol-Myers Squibb Company
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Treatment Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Novartis AG
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Treatment Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. F. Hoffmann-La Roche Ltd
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Treatment Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Merck KGaA
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Treatment Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Sanofi
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Treatment Benchmarking
7.5.10.4. Strategic Initiatives
7.5.11. Alnylam Pharmaceuticals, Inc.
7.5.11.1. Overview
7.5.11.2. Financial Performance
7.5.11.3. Treatment Benchmarking
7.5.11.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global amyloidosis treatment market, by region, 2021 – 2033 (USD Million)
Table 4 Global amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 5 Global amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 6 North America amyloidosis treatment market, by country, 2021 – 2033 (USD Million)
Table 7 North America amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 8 North America amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 9 U.S. amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 10 U.S. amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 11 Canada amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 12 Canada amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 13 Mexico amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 14 Mexico amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 15 Europe amyloidosis treatment market, by country, 2021 – 2033 (USD Million)
Table 16 Europe amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 17 Europe amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 18 UK amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 19 UK amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 20 Germany amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 21 Germany amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 22 France amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 23 France amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 24 Italy amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 25 Italy amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 26 Spain amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 27 Spain amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 28 Norway amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 29 Norway amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 30 Denmark amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 31 Denmark amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 32 Sweden amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 33 Sweden amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 34 Asia Pacific amyloidosis treatment market, by country, 2021 – 2033 (USD Million)
Table 35 Asia Pacific amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 36 Asia Pacific amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 37 Japan amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 38 Japan amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 39 China amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 40 China amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 41 India amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 42 India amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 43 Australia amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 44 Australia amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 45 South Korea amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 46 South Korea amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 47 Thailand amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 48 Thailand amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 49 Latin America amyloidosis treatment market, by country, 2021 – 2033 (USD Million)
Table 50 Latin America amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 51 Latin America amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 52 Brazil amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 53 Brazil amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 54 Argentina amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 55 Argentina amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 56 Middle East & Africa Amyloidosis treatment market, by country, 2021 – 2033 (USD Million)
Table 57 Middle East & Africa amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 58 Middle East & Africa amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 59 South Africa amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 60 South Africa amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 61 Saudi Arabia amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 62 Saudi Arabia amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 63 UAE amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 64 UAE amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
Table 65 Kuwait amyloidosis treatment market, by treatment, 2021 – 2033 (USD Million)
Table 66 Kuwait amyloidosis treatment market, by end-use, 2021 – 2033 (USD Million)
List of Figures
Fig. 1 Amyloidosis treatment market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and treatment outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Amyloidosis treatment market dynamics
Fig. 12 Amyloidosis treatment market: Porter’s five forces analysis
Fig. 13 Amyloidosis treatment market: PESTLE analysis
Fig. 14 Treatment market, 2021 – 2033 (USD Million)
Fig. 15 Chemotherapy market, 2021 – 2033 (USD Million)
Fig. 16 Immunosuppressive drugs market, 2021 – 2033 (USD Million)
Fig. 17 Transplantation market, 2021 – 2033 (USD Million)
Fig. 18 Supportive care market, 2021 – 2033 (USD Million)
Fig. 19 Surgery market, 2021 – 2033 (USD Million)
Fig. 20 Others market, 2021 – 2033 (USD Million)
Fig. 21 End use market, 2021 – 2033 (USD Million)
Fig. 22 Hospitals & clinics market, 2021 – 2033 (USD Million)
Fig. 23 Ambulatory surgical centers market, 2021 – 2033 (USD Million)
Fig. 24 Home care settings market, 2021 – 2033 (USD Million)
Fig. 25 Others market, 2021 – 2033 (USD Million)
Fig. 26 Amyloidosis treatment market revenue, by region
Fig. 27 Regional marketplace: Key takeaways
Fig. 28 North America amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 29 U.S. country dynamics
Fig. 30 U.S. amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 31 Canada country dynamics
Fig. 32 Canada amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 33 Mexico country dynamics
Fig. 34 Mexico amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 35 Europe amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 36 UK country dynamics
Fig. 37 UK amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 38 Germany country dynamics
Fig. 39 Germany amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 40 France country dynamics
Fig. 41 France amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 42 Italy country dynamics
Fig. 43 Italy amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 44 Spain country dynamics
Fig. 45 Spain amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 46 Norway country dynamics
Fig. 47 Norway amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 48 Sweden country dynamics
Fig. 49 Sweden amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 50 Denmark country dynamics
Fig. 51 Denmark amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 52 Asia Pacific amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 53 Japan country dynamics
Fig. 54 Japan amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 55 China country dynamics
Fig. 56 China amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 57 India country dynamics
Fig. 58 India amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 59 Australia country dynamics
Fig. 60 Australia amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 61 South Korea country dynamics
Fig. 62 South Korea amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 63 Thailand country dynamics
Fig. 64 Thailand amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 65 Latin America amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 66 Brazil country dynamics
Fig. 67 Brazil amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 68 Argentina country dynamics
Fig. 69 Argentina amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 70 MEA amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 71 South Africa country dynamics
Fig. 72 South Africa amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 73 Saudi Arabia country dynamics
Fig. 74 Saudi Arabia amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 75 UAE country dynamics
Fig. 76 UAE amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 77 Kuwait country dynamics
Fig. 78 Kuwait amyloidosis treatment market, 2021 – 2033 (USD Million)
Fig. 79 Company categorization
Fig. 80 Company market position analysis
Fig. 81 Strategic framework
Grand View Researchについて
Grand View Research（グランドビューリサーチ） はインドと米国を拠点とする市場調査およびコンサルティング会社です。世界中主要 25ヵ国・ 46 業界に関する豊富なデータベースを活用した市場情報は世界の企業団体に活用・引用されています。日本からのレポートのご注文・ご購入相談はお気軽にお問い合わせください。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ 1
| シングルユーザ | チーム | エンタープライズ |
| USD 2,950 | USD 3,950 | USD 5,950 |
ライセンスタイプ 2
| シングルユーザ | チーム | エンタープライズ |
| USD 3,950 | USD 4,950 | USD 6,950 |
ライセンスタイプ 3
| シングルユーザ | チーム | エンタープライズ |
| USD 4,950 | USD 5,950 | USD 7,950 |
ライセンスタイプ 4
| シングルユーザ | チーム | エンタープライズ |
| USD 5,950 | USD 6,950 | USD 8,950 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス（インディビジュアルライセンス）
- 1名のみレポートファイル（印刷不可）をご利用いただけます。
- チームライセンス
- 同一企業（関連会社除く）内5名まで共有可能です。印刷可能な電子ファイルをご提供いたします。
- コーポレートライセンス
- 同一企業および関連会社内で人数無制限で共有可能です。印刷可能な電子ファイルをご提供いたします。
- 「関連会社」の範囲についてはお気軽にお問い合わせください。
- シングルユーザライセンス（インディビジュアルライセンス）
- 納品形態
- オンラインダウンロード
- 納期
- ご注文後1～7営業日 ※レポートにより異なります。
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
最新出版レポート